In a committee room in Bethesda last month, more than sixty employees of the National Institutes of Health signed a letter to their own director accusing him of presiding over the politicisation of American medicine. They called it the Bethesda Declaration, a deliberate echo of the anti-lockdown manifesto that had made Jay Bhattacharya's name five years earlier. The irony was not lost on anyone in the room. A man who built his public reputation resisting one form of politically driven public health orthodoxy now stood accused of installing another.

The proposal now moving through the White House is more consequential than the letter that provoked it. Draft regulations from the Office of Management and Budget would give political appointees, rather than scientific reviewers, final and effectively unaccountable authority over federal research grants. Peer review, the mechanism that has allocated American biomedical funding since 1946, would become advisory. A grant could be refused or withdrawn because its subject matter, its language or its institutional affiliations displeased the administration of the day, with no requirement to explain the decision and no clear route of appeal.

For NHS leaders and UK policymakers watching from a distance, the temptation is to treat this as a uniquely American pathology, a product of a political culture that has spent a decade treating expertise as a partisan category. That temptation should be resisted. The mechanism being tested in Washington, the subordination of technical judgement to political sign-off, is not confined by geography, and Britain's own health and science institutions are more entangled with it than they might like to admit.

The practical exposure begins with money and collaboration. NIH funding underwrites a substantial share of the international clinical trials infrastructure that NHS trusts and UK universities plug into, and a slower, more arbitrary grant process in America does not stay in America. Delayed or cancelled NIH awards can stall multinational trials in which UK sites are recruiting patients, disrupt the academic partnerships that feed genomics and oncology research at institutions linked to Genomics England and the UK Biobank, and unsettle the transatlantic investment flows that underpin the government's stated ambition to make Britain a life sciences superpower. None of this requires a single UK grant to be touched. It only requires American funding to become less predictable.

There is a second, more structural resonance. The NHS has spent much of the past decade negotiating its own version of the tension now visible in Washington, the pull between clinical and scientific judgement on one side and political direction on the other. Waiting list targets, productivity metrics and ministerial interventions in operational decisions are not the same as a formal veto over research funding, but they belong to the same family of instinct, the belief that outcomes improve when political authority overrides professional discretion. British research funding bodies, including UK Research and Innovation, have generally kept a firmer boundary between ministers and grant decisions than their American counterpart is now proposing to abandon. That boundary is a convention rather than a constitutional guarantee, and conventions have proven negotiable elsewhere in recent years.

The Trump administration frames its proposal as fiscal discipline and accountability, a corrective to a scientific establishment it regards as self-selecting and unaccountable to elected government. There is a genuine argument buried in that framing, about transparency in how public research money is allocated, that UK policymakers should not dismiss simply because of who is making it. But the remedy on offer, unaccountable political veto without published reasoning or appeal, does not address that argument so much as replace one unaccountable process with another.

What British health leaders should take from this is narrower than a warning about American politics and sharper than a lesson in comparative government. It is a reminder that the institutional habits protecting scientific decisions from short-term political pressure are maintained by continuous practice, not by permanent design, and that the same instinct now reshaping grantmaking in Washington has domestic cousins already active in how the NHS is run.

‍